which inhibits the biosynthesis of mycolic acids that are a key component of the cell walls of mycobacteria — is also in Phase II clinical trials to treat patients with MDR-TB, but no results ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback